Clinical Trials Logo

Clinical Trial Summary

A randomized, double-blind, placebo controlled study to assess the safety and effectiveness of a novel oral natural extract to improve the appearance of the skin of patients with senile purpura.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)


Related Conditions & MeSH terms


NCT number NCT01183910
Study type Interventional
Source Nexgen Dermatologics, Inc.
Contact
Status Active, not recruiting
Phase N/A
Start date November 2008
Completion date August 2011

See also
  Status Clinical Trial Phase
Completed NCT00272610 - Topical Vitamin A Versus Vehicle Cream in the Treatment of Aged Skin Phase 2
Completed NCT01525836 - rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP Phase 3
Active, not recruiting NCT03499808 - S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis Phase 2
Completed NCT01506414 - Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP) Phase 3
Completed NCT01910831 - Study to Assess DerMend Moisturizing Bruise Formula in Improving the Appearance of Chronically Aged Forearms and Hands Phase 4
Withdrawn NCT01734057 - Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) Phase 3
Completed NCT01734044 - rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITP Phase 3
Withdrawn NCT01882127 - All-Trans Retinoic Acid (ATRA) Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) Phase 3
Recruiting NCT06291415 - The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP) Phase 1